CRISPRs
AssigneeExcision Biotherapeutics, Inc.
InventorThomas Malcolm
Life of this patent
Estimating the term…
Abstract
A composition for treating a lysogenic virus, including a vector encoding isolated nucleic acid encoding two or more gene editors chosen from gene editors that target viral DNA, gene editors that target viral RNA, and combinations thereof. A composition for treating a lytic virus, including a vector encoding isolated nucleic acid encoding at least one gene editor that targets viral DNA and a viral RNA targeting composition. A composition for treating both lysogenic and lytic viruses, including a vector encoding isolated nucleic acid encoding two or more gene editors that target viral RNA. A composition for treating lytic viruses. Methods of treating a lysogenic virus or a lytic virus, by administering the above compositions to an individual having a virus and inactivating the virus.
Claims52
A composition for treating a lysogenic virus, comprising a vector encoding isolated nucleic acid encoding two or more gene editors chosen from the group consisting of gene editors that target viral DNA, gene editors that target viral RNA, and combinations thereof.
A composition for treating a lytic virus, comprising a vector encoding isolated nucleic acid encoding at least one gene editor that targets viral DNA and a viral RNA targeting composition.
A composition for treating both lysogenic and lytic viruses, comprising a vector encoding isolated nucleic acid encoding two or more gene editors that target viral RNA, chosen from the group consisting of CRISPR-associated nucleases, Argonaute endonuclease gDNAs, C2c2, RNase P RNA, and combinations thereof.
A composition for treating lytic viruses, comprising a vector encoding isolated nucleic acid encoding two or more gene editors that target viral RNA and a viral RNA targeting composition.
A method of treating a lysogenic virus, including the steps of:
- administering a composition including a vector encoding isolated nucleic acid encoding two or more gene editors chosen from the group consisting of gene editors that target viral DNA, gene editors that target viral RNA, and combinations thereof to an individual having a lysogenic virus;
- and
- inactivating the lysogenic virus.
A method for treating a lytic virus, including the steps of:
- administering a composition including a vector encoding isolated nucleic acid encoding at least one gene editor that targets viral DNA and a viral RNA targeting composition to an individual having a lytic virus;
- and
- inactivating the lytic virus.
A method for treating both lysogenic and lytic viruses, including the steps of:
- administering a composition including a vector encoding isolated nucleic acid encoding two or more gene editors that target viral RNA, chosen from the group consisting of CRISPR-associated nucleases, Argonaute endonuclease gDNAs, C2c2, RNase P RNA, and combinations thereof to an individual having a lysogenic virus and lytic virus;
- and
- inactivating the lysogenic virus and lytic virus.
A method for treating lytic viruses, including the steps of:
- administering a composition including a vector encoding isolated nucleic acid encoding two or more gene editors that target viral RNA and a viral RNA targeting composition to an individual having a lytic virus;
- and
- inactivating the lytic virus.
Dependencies are inferred from the claim text.